290 related articles for article (PubMed ID: 17599035)
21. Tumour necrosis factor alpha down-regulation parallels inflammatory regression in ulcerative colitis patients treated with infliximab.
Hassan C; Ierardi E; Burattini O; De Francesco V; Zullo A; Stoppino G; Panella C; Morini S
Dig Liver Dis; 2007 Sep; 39(9):811-7. PubMed ID: 17652038
[TBL] [Abstract][Full Text] [Related]
22. Ultrastructural evidence of mucosal healing after infliximab in patients with ulcerative colitis.
Fratila OC; Craciun C
J Gastrointestin Liver Dis; 2010 Jun; 19(2):147-53. PubMed ID: 20593047
[TBL] [Abstract][Full Text] [Related]
23. Adalimumab in ulcerative colitis: hypes and hopes.
Fiorino G; Peyrin-Biroulet L; Repici A; Malesci A; Danese S
Expert Opin Biol Ther; 2011 Jan; 11(1):109-16. PubMed ID: 21133817
[TBL] [Abstract][Full Text] [Related]
24. [Use of infliximab in ulcerative colitis].
Tilg H; Feichtenschlager T; Knoflach P; Petritsch W; Schöfl R; Vogelsang H; Reinisch W
Z Gastroenterol; 2007 Aug; 45(8):907-11. PubMed ID: 17701864
[TBL] [Abstract][Full Text] [Related]
25. [Treatment of servere ulcerative colitis].
Weersma RK; van Dullemen HM; Kleibeuker JH; Ploeg RJ; Dijkstra G
Ned Tijdschr Geneeskd; 2006 Jan; 150(1):12-7. PubMed ID: 16440618
[TBL] [Abstract][Full Text] [Related]
26. Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: a Korean multicenter retrospective study.
Lee KM; Jeen YT; Cho JY; Lee CK; Koo JS; Park DI; Im JP; Park SJ; Kim YS; Kim TO; Lee SH; Jang BI; Kim JW; Park YS; Kim ES; Choi CH; Kim HJ;
J Gastroenterol Hepatol; 2013 Dec; 28(12):1829-33. PubMed ID: 23829336
[TBL] [Abstract][Full Text] [Related]
27. Anti-TNF-A Therapy about Infliximab and Adalimamab for the Effectiveness in Ulcerative Colitis Compared with Conventional Therapy: A Meta-Analysis.
Zhou Z; Dai C; Liu WX
Hepatogastroenterology; 2015 Jun; 62(140):829-37. PubMed ID: 26902011
[TBL] [Abstract][Full Text] [Related]
28. Infliximab therapy downregulation of basic fibroblast growth factor/syndecan 1 link: a possible molecular pathway of mucosal healing in ulcerative colitis.
Ierardi E; Giorgio F; Zotti M; Rosania R; Principi M; Marangi S; Della Valle N; De Francesco V; Di Leo A; Ingrosso M; Panella C
J Clin Pathol; 2011 Nov; 64(11):968-72. PubMed ID: 21945924
[TBL] [Abstract][Full Text] [Related]
29. [TNF-alpha antibody treatment and remission induction in ulcerative colitis: a review of a Cochrane review].
Bjerrum JT; Munck LC; Krogh-Madsen M; Nielsen OH
Ugeskr Laeger; 2007 Feb; 169(9):792-5. PubMed ID: 17355842
[No Abstract] [Full Text] [Related]
30. Short- and long-term response to and weaning from infliximab therapy in pediatric ulcerative colitis.
Fanjiang G; Russell GH; Katz AJ
J Pediatr Gastroenterol Nutr; 2007 Mar; 44(3):312-7. PubMed ID: 17325550
[TBL] [Abstract][Full Text] [Related]
31. Do anti-tumor necrosis factors induce response and remission in patients with acute refractory Crohn's disease? A systematic meta-analysis of controlled clinical trials.
Rahimi R; Nikfar S; Abdollahi M
Biomed Pharmacother; 2007 Jan; 61(1):75-80. PubMed ID: 17184965
[TBL] [Abstract][Full Text] [Related]
32. Infliximab for the treatment of ulcerative colitis.
Eshuis EJ; Bemelman WA; Stokkers PC
Expert Rev Gastroenterol Hepatol; 2009 Jun; 3(3):219-29. PubMed ID: 19485804
[TBL] [Abstract][Full Text] [Related]
33. Refractory Takayasu arteritis successfully treated with infliximab.
Maffei S; Di Renzo M; Santoro S; Puccetti L; Pasqui AL
Eur Rev Med Pharmacol Sci; 2009; 13(1):63-5. PubMed ID: 19364087
[TBL] [Abstract][Full Text] [Related]
34. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2.
Sandborn WJ; Colombel JF; D'Haens G; Van Assche G; Wolf D; Kron M; Lazar A; Robinson AM; Yang M; Chao JD; Thakkar R
Aliment Pharmacol Ther; 2013 Jan; 37(2):204-13. PubMed ID: 23173821
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness of infliximab in Brazilian children and adolescents with Crohn disease and ulcerative colitis according to clinical manifestations, activity indices of inflammatory bowel disease, and corticosteroid use.
Tiemi J; Komati S; Sdepanian VL
J Pediatr Gastroenterol Nutr; 2010 Jun; 50(6):628-33. PubMed ID: 20386321
[TBL] [Abstract][Full Text] [Related]
36. Infliximab for pediatric ulcerative colitis: a retrospective Italian multicenter study.
Cucchiara S; Romeo E; Viola F; Cottone M; Fontana M; Lombardi G; Rutigliano V; de'Angelis GL; Federici T
Dig Liver Dis; 2008 Jul; 40 Suppl 2():S260-4. PubMed ID: 18598998
[TBL] [Abstract][Full Text] [Related]
37. Pre-operative use of anti-TNF-α agents and the risk of post-operative complications in patients with ulcerative colitis - a nationwide cohort study.
Nørgård BM; Nielsen J; Qvist N; Gradel KO; de Muckadell OB; Kjeldsen J
Aliment Pharmacol Ther; 2012 Jun; 35(11):1301-9. PubMed ID: 22506582
[TBL] [Abstract][Full Text] [Related]
38. Outcome following infliximab therapy in children with ulcerative colitis.
Hyams JS; Lerer T; Griffiths A; Pfefferkorn M; Stephens M; Evans J; Otley A; Carvalho R; Mack D; Bousvaros A; Rosh J; Grossman A; Tomer G; Kay M; Crandall W; Oliva-Hemker M; Keljo D; LeLeiko N; Markowitz J;
Am J Gastroenterol; 2010 Jun; 105(6):1430-6. PubMed ID: 20104217
[TBL] [Abstract][Full Text] [Related]
39. Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study.
Bosca-Watts MM; Cortes X; Iborra M; Huguet JM; Sempere L; Garcia G; Gil R; Garcia M; Muñoz M; Almela P; Maroto N; Paredes JM
World J Gastroenterol; 2016 Dec; 22(47):10432-10439. PubMed ID: 28058024
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: Meta-analysis of placebo-controlled trials.
Lopez A; Ford AC; Colombel JF; Reinisch W; Sandborn WJ; Peyrin-Biroulet L
Dig Liver Dis; 2015 May; 47(5):356-64. PubMed ID: 25661014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
